A Neuron-specific Methyl-histone Regulatory Complex
神经元特异性甲基组蛋白调节复合物
基本信息
- 批准号:10615745
- 负责人:
- 金额:$ 48.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AT-Hook MotifsAddressAdoptedAffectAffinityAlternative SplicingBindingBiochemistryBrainCancer cell lineCatalytic DomainCellsCellular biologyChromatinChromatin Remodeling FactorChromatin StructureComplementComplexCryoelectron MicroscopyDNADNA BindingDNA SequenceDataDefectDevelopmentDiseaseEnzymesExcitatory SynapseExonsGene ExpressionGenomic approachGoalsHigher Order Chromatin StructureHistone H3HistonesHumanHuman GeneticsImpairmentIn VitroIntellectual functioning disabilityInvestigationKDM1A geneKnock-outKnowledgeLeadLysineMediatingMediatorMissense MutationModelingMusMutateNeurodevelopmental DisorderNeuronsNucleosomesNucleotidesOrganPHD FingerPathogenesisPathologicPatientsPattern RecognitionPlayProtein IsoformsPublishingRNA SplicingReactionReaderRegulationReportingResearchRoleSpecificitySubstrate SpecificityTestingautism spectrum disordercell typechromatin modificationdemethylationdesignembryonic stem cellexperimental studyfunctional genomicshistone demethylasehistone methylationhistone modificationin vivoinsightinterdisciplinary approachmouse modelneurodevelopmentnovel strategiesprotein protein interactionreconstitutionrecruitstructural biologysynaptogenesistherapeutic targettranscription factortranscriptome
项目摘要
Abstract
It is widely accepted that cell-type-specific gene expression is primarily achieved by cell-type-specific
presence of transcription factors (TFs), which bind to cognate DNA sequences. TFs then initiate changes in
higher-order chromatin structures by recruiting chromatin modifiers, including histone-modifying enzymes.
Unlike TFs, chromatin modifiers tend to be ubiquitously expressed. Among the plethora of chromatin
modifications, regulators of histone methylation are more frequently mutated in neurodevelopmental disorders
(NDDs) such as intellectual disabilities (IDs) and autism. Why is the brain so sensitive to dysregulation of
histone methylation? Is methyl-histone regulation in neurons unique? Investigation of a limited number of cell
types, cancer-cell lines, and embryonic stem cells has hampered our ability to address these questions.
The overarching goal of my research group is to contribute to the understanding of how methyl-histone
regulations underlie normal and pathological brain functions. Our focus is on the LSD1-PHF21A histone-
demethylation complex, which involves neuron-specific alternative splicing. LSD1 is a histone demethylase for
histone H3 lysine 4 (H3K4me). PHF21A was the first-discovered “zero reader,” which recognizes unmethylated
H3K4 (H3K4me0), the reaction product of canonical LSD1 (LSD1-c). Both LSD1 and PHF21A
haploinsufficiencies lead to NDDs, suggesting their importance in brain development. The neuronal LSD1
isoform (LSD1-n), which carries an alternative exon in its catalytic domain, was reported to have distinct
substrate specificity. However, the specific lysine(s) targeted by LSD1-n remains controversial. The goal of this
proposal is to determine the roles of the neuronal LSD1-PHF21A complex. Our preliminary study showed that
PHF21A also carries an alternative exon right upstream of the H3K4me0-recognizing PHD finger. This region
of PHF21A contains an AT-hook motif, which directly binds to DNA; we found that the alternative exon disrupts
the AT-hook, hence the DNA binding, but not H3K4me0 binding. These observations raise an exciting
possibility that the neuronal PHF21A isoform (PHF21A-n) recognizes nucleosomes in a distinct manner
compared to canonical PHF21A (PHF21A-c), thereby cooperating with LSD1-n to generate the neuronal
transcriptome for normal brain development.
We propose testing the hypothesis using multidisciplinary approaches encompassing cell biology,
biochemistry, and structural biology. The research plan was developed to provide both mechanistic insights
into the regulation of histone modifications and a better understanding of the pathogenesis of
neurodevelopment disorders, which could lead to novel approaches for brain-specific therapeutic targets.
抽象的
广泛接受的是,细胞型特异性基因表达主要是通过细胞型特异性实现的
转录因子(TFS)的存在,与同源DNA序列结合。然后TF启动更改
高阶染色质结构通过募集染色质修饰剂(包括组蛋白修饰酶)。
与TF不同,染色质修饰剂往往会普遍表达。在大量的染色质中
修饰,组蛋白甲基化的调节剂在神经发育障碍中更频繁地突变
(NDD),例如智力残疾(IDS)和自闭症。为什么大脑对失调的敏感
组蛋白甲基化?神经元中的甲基 - 历史调节是独一无二的吗?研究有限数量的细胞
类型,癌细胞系和胚胎干细胞阻碍了我们解决这些问题的能力。
我的研究小组的总体目标是有助于理解甲基持有物的方式
法规是正常和病理大脑功能的基础。我们的重点是LSD1-PHF21A Hisstone-
去甲基化复合物,涉及神经特异性的替代剪接。 LSD1是一种组蛋白脱甲基酶
组蛋白H3赖氨酸4(H3K4ME)。 PHF21A是第一发现的“零读者”,它识别未甲基化的
H3K4(H3K4ME0),规范LSD1(LSD1-C)的反应产物。 LSD1和PHF21A均
单倍延伸导致NDD,这表明它们在大脑发育中的重要性。神经元LSD1
据报道,同工型(LSD1-N)具有催化结构域中的替代外显子,据报道具有不同的
底物特异性。但是,由LSD1-N靶向的特定赖氨酸仍存在争议。目标的目标
建议是确定神经元LSD1-PHF21A复合物的作用。我们的初步研究表明
PHF21A还在H3K4ME0识别的PhD手指的上游带有另一种外显子。这个区域
PHF21a的含有一个直接与DNA结合的at钩基序。我们发现替代外显子破坏了
钩子,因此DNA结合,而不是H3K4me0结合。这些观察引起了令人兴奋的
神经元PHF21A同工型(PHF21A-N)以不同的方式识别核体的可能性
与规范PHF21A(PHF21A-C)相比,与LSD1-N合作生成神经元
正常脑发育的转录组。
我们提出了使用涵盖细胞生物学的多学科方法来检验假设的,
生物化学和结构生物学。制定了研究计划以提供两个机械见解
进入组蛋白修饰的调节,并更好地理解
神经发育障碍,这可能导致新的脑特异性治疗靶标的方法。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Batch Production of High-Quality Graphene Grids for Cryo-EM: Cryo-EM Structure of Methylococcus capsulatus Soluble Methane Monooxygenase Hydroxylase.
- DOI:10.1021/acsnano.3c00463
- 发表时间:2023-03-28
- 期刊:
- 影响因子:17.1
- 作者:Ahn, Eungjin;Kim, Byungchul;Park, Soyoung;Erwin, Amanda L.;Sung, Suk Hyun;Hovden, Robert;Mosalaganti, Shyamal;Cho, Uhn-Soo
- 通讯作者:Cho, Uhn-Soo
A neuron-specific microexon ablates the novel DNA-binding function of a histone H3K4me0 reader PHF21A.
神经元特异性微外显子消除了组蛋白 H3K4me0 阅读器 PHF21A 的新型 DNA 结合功能。
- DOI:10.1101/2023.10.20.563357
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Porter,RobertS;Nagai,Masayoshi;An,Sojin;Gavilan,MariaC;Murata-Nakamura,Yumie;Bonefas,KatherineM;Zhou,Bo;Dionne,Olivier;Manuel,JeruManoj;St-Germain,Joannie;Browning,Liam;Laurent,Benoit;Cho,Uhn-Soo;Iwase,Shigeki
- 通讯作者:Iwase,Shigeki
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shigeki Iwase其他文献
Shigeki Iwase的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shigeki Iwase', 18)}}的其他基金
Diurnal Experimental Models to Investigate Neural Mechanisms of Sleep Disturbance in Smith-Magenis Syndrome
研究史密斯-马吉尼斯综合征睡眠障碍神经机制的昼夜实验模型
- 批准号:
10359869 - 财政年份:2021
- 资助金额:
$ 48.22万 - 项目类别:
A Neuron-specific Methyl-histone Regulatory Complex
神经元特异性甲基组蛋白调节复合物
- 批准号:
10401853 - 财政年份:2020
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
9266842 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
9085410 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
8964042 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopment disorders
中和神经发育障碍中的表观基因组
- 批准号:
9233642 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Implementation of Innovative Treatment for Moral Injury Syndrome: A Hybrid Type 2 Study
道德伤害综合症创新治疗的实施:2 型混合研究
- 批准号:
10752930 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Creation of a knowledgebase of high quality assertions of the clinical actionability of somatic variants in cancer
创建癌症体细胞变异临床可行性的高质量断言知识库
- 批准号:
10555024 - 财政年份:2023
- 资助金额:
$ 48.22万 - 项目类别:
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 48.22万 - 项目类别:
Paid Sick Leave Mandates and Mental Healthcare Service Use
带薪病假规定和心理保健服务的使用
- 批准号:
10635492 - 财政年份:2023
- 资助金额:
$ 48.22万 - 项目类别:
DRUG DISCOVERY BY DIRECTED EVOLUTION IN MAMMALIAN CELLS
通过哺乳动物细胞定向进化发现药物
- 批准号:
10644749 - 财政年份:2023
- 资助金额:
$ 48.22万 - 项目类别: